JP2005502315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005502315A5 JP2005502315A5 JP2002574050A JP2002574050A JP2005502315A5 JP 2005502315 A5 JP2005502315 A5 JP 2005502315A5 JP 2002574050 A JP2002574050 A JP 2002574050A JP 2002574050 A JP2002574050 A JP 2002574050A JP 2005502315 A5 JP2005502315 A5 JP 2005502315A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- expression
- mutation
- mannheimia
- gene product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims 25
- 230000035772 mutation Effects 0.000 claims 14
- 241000894006 Bacteria Species 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 9
- 239000002157 polynucleotide Substances 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 241001293415 Mannheimia Species 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 230000007423 decrease Effects 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 108020004414 DNA Proteins 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 241000894007 species Species 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241001293418 Mannheimia haemolytica Species 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 235000015097 nutrients Nutrition 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 101000798869 Escherichia phage Mu DDE-recombinase A Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000001018 virulence Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/809,665 US6790950B2 (en) | 1999-04-09 | 2001-03-15 | Anti-bacterial vaccine compositions |
| PCT/US2002/001971 WO2002075507A2 (en) | 2001-03-15 | 2002-01-17 | Anti-bacterial vaccine compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010247585A Division JP2011097938A (ja) | 2001-03-15 | 2010-11-04 | 抗菌性ワクチン組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005502315A JP2005502315A (ja) | 2005-01-27 |
| JP2005502315A5 true JP2005502315A5 (enExample) | 2006-01-05 |
Family
ID=25201919
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002574050A Pending JP2005502315A (ja) | 2001-03-15 | 2002-01-17 | 抗菌性ワクチン組成物 |
| JP2010247585A Pending JP2011097938A (ja) | 2001-03-15 | 2010-11-04 | 抗菌性ワクチン組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010247585A Pending JP2011097938A (ja) | 2001-03-15 | 2010-11-04 | 抗菌性ワクチン組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6790950B2 (enExample) |
| EP (1) | EP1368456B1 (enExample) |
| JP (2) | JP2005502315A (enExample) |
| AR (2) | AR035745A1 (enExample) |
| AT (1) | ATE500316T1 (enExample) |
| AU (1) | AU2002240033B2 (enExample) |
| CA (2) | CA2438315C (enExample) |
| CY (1) | CY1112014T1 (enExample) |
| DE (1) | DE60239318D1 (enExample) |
| DK (1) | DK1368456T3 (enExample) |
| ES (1) | ES2362041T3 (enExample) |
| MX (1) | MXPA03008296A (enExample) |
| NZ (1) | NZ528208A (enExample) |
| PE (1) | PE20021008A1 (enExample) |
| PT (1) | PT1368456E (enExample) |
| SI (1) | SI1368456T1 (enExample) |
| TW (4) | TWI335935B (enExample) |
| WO (1) | WO2002075507A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455323B1 (en) * | 1997-07-03 | 2002-09-24 | Pharmacia & Upjohn Company | Anti-bacterial methods and materials |
| US6790950B2 (en) * | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
| JP4892134B2 (ja) * | 1999-04-09 | 2012-03-07 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 抗菌ワクチン組成物 |
| WO2002034771A2 (en) | 2000-10-27 | 2002-05-02 | Chiron Srl | Nucleic acids and proteins from streptococcus groups a & b |
| US7449178B2 (en) * | 2002-04-05 | 2008-11-11 | Merial Limited | Attenuated gram negative bacteria |
| US7794734B2 (en) * | 2002-10-30 | 2010-09-14 | The Board Of Regents For Oklahoma State University | Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever |
| GB0228691D0 (en) * | 2002-12-09 | 2003-01-15 | Imp College Innovations Ltd | Bacterial virulence genes |
| EP1648500B1 (en) | 2003-07-31 | 2014-07-09 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for streptococcus pyogenes |
| US8945589B2 (en) | 2003-09-15 | 2015-02-03 | Novartis Vaccines And Diagnostics, Srl | Immunogenic compositions for Streptococcus agalactiae |
| US9107864B2 (en) * | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| EP2073829B1 (en) * | 2006-10-05 | 2012-06-20 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| US8937154B2 (en) | 2006-10-05 | 2015-01-20 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| AU2008299376B2 (en) | 2007-09-12 | 2013-02-28 | Glaxosmithkline Biologicals S.A. | GAS57 mutant antigens and GAS57 antibodies |
| JP2011522796A (ja) | 2008-05-06 | 2011-08-04 | ニューヨーク ブラッド センター， インコーポレイテッド | 抗ウイルス細胞透過性ペプチド |
| CA2729818A1 (en) * | 2008-07-03 | 2010-01-07 | Biotechnology Research And Development Corporation | Vaccines comprising pasteurella multocida recombinant filamentous hemagglutinin peptides |
| CA2774636C (en) | 2009-09-25 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9757445B2 (en) | 2013-11-01 | 2017-09-12 | Merial Inc. | Attenuated Pasteurella multocida vaccines and methods of making and use thereof |
| CN116593695B (zh) * | 2022-12-29 | 2025-08-05 | 重庆澳龙生物制品有限公司 | 一种牛多杀性巴氏杆菌荚膜a型elisa抗体检测试剂盒及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4735801A (en) | 1982-09-07 | 1988-04-05 | Board Of Trustees Of Leland Stanford Jr. University | Novel non-reverting salmonella live vaccines |
| US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| US4877612A (en) | 1985-05-20 | 1989-10-31 | Frank M. Berger | Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process |
| DK166762B1 (da) | 1986-01-14 | 1993-07-12 | Nederlanden Staat | Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser |
| US4806352A (en) | 1986-04-15 | 1989-02-21 | Ribi Immunochem Research Inc. | Immunological lipid emulsion adjuvant |
| CA1340522C (en) | 1987-03-10 | 1999-05-04 | Heinz Dobeli | Fusion proteins containing neighbouring histidines for improved purification |
| IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| PL170938B1 (pl) | 1991-03-05 | 1997-02-28 | Wellcome Found | Sposób wytwarzania szczepionki przeciwko infekcjom Salmonella PL PL |
| US5840312A (en) | 1991-05-02 | 1998-11-24 | Institut Pasteur | Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein |
| WO1994011024A1 (en) | 1992-11-06 | 1994-05-26 | Regents Of The University Of Minnesota | Composition protective against p. multocida pasteurellosis infection |
| US5585277A (en) | 1993-06-21 | 1996-12-17 | Scriptgen Pharmaceuticals, Inc. | Screening method for identifying ligands for target proteins |
| WO1995020652A1 (de) | 1994-01-28 | 1995-08-03 | Medigene Gmbh | Verfahren zur bestimmung der aktivität eines regulatorischen faktors sowie verwendung dieses verfahrens |
| KR100445103B1 (ko) | 1994-12-09 | 2004-12-04 | 임페리얼 컬리지 이노베이션스 리미티드 | 유전자의동정 |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| BR9713195A (pt) * | 1996-09-06 | 1999-12-21 | Peter Ruhdal Jensen | Método de aperfeiçoamento da produção de biomassa ou de um produto desejado de uma célula. |
| US6673538B1 (en) * | 1997-07-25 | 2004-01-06 | The Trustees Of Boston University | Methods and compositions for designing vaccines |
| US6790950B2 (en) * | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
| JP4892134B2 (ja) | 1999-04-09 | 2012-03-07 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 抗菌ワクチン組成物 |
| US6376211B1 (en) * | 1999-07-12 | 2002-04-23 | Xoma Technology Ltd. | Agents and methods for inhibiting F1/F0 ATPase |
| DE60124526D1 (de) * | 2000-04-27 | 2006-12-28 | Max Planck Gesellschaft | Methode zur identifizierung von helicobacter antigenen |
-
2001
- 2001-03-15 US US09/809,665 patent/US6790950B2/en not_active Expired - Lifetime
-
2002
- 2002-01-17 MX MXPA03008296A patent/MXPA03008296A/es active IP Right Grant
- 2002-01-17 CA CA2438315A patent/CA2438315C/en not_active Expired - Lifetime
- 2002-01-17 CA CA2852293A patent/CA2852293A1/en not_active Abandoned
- 2002-01-17 ES ES02705915T patent/ES2362041T3/es not_active Expired - Lifetime
- 2002-01-17 EP EP02705915A patent/EP1368456B1/en not_active Expired - Lifetime
- 2002-01-17 AU AU2002240033A patent/AU2002240033B2/en not_active Expired
- 2002-01-17 NZ NZ528208A patent/NZ528208A/en not_active IP Right Cessation
- 2002-01-17 DE DE60239318T patent/DE60239318D1/de not_active Expired - Lifetime
- 2002-01-17 DK DK02705915.3T patent/DK1368456T3/da active
- 2002-01-17 WO PCT/US2002/001971 patent/WO2002075507A2/en not_active Ceased
- 2002-01-17 JP JP2002574050A patent/JP2005502315A/ja active Pending
- 2002-01-17 AT AT02705915T patent/ATE500316T1/de active
- 2002-01-17 SI SI200230939T patent/SI1368456T1/sl unknown
- 2002-01-17 PT PT02705915T patent/PT1368456E/pt unknown
- 2002-02-07 AR ARP020100402A patent/AR035745A1/es not_active Application Discontinuation
- 2002-02-08 TW TW099122913A patent/TWI335935B/zh not_active IP Right Cessation
- 2002-02-08 TW TW099122912A patent/TWI335934B/zh not_active IP Right Cessation
- 2002-02-08 TW TW091102640A patent/TWI328035B/zh not_active IP Right Cessation
- 2002-02-08 TW TW097148939A patent/TWI334884B/zh not_active IP Right Cessation
- 2002-02-27 PE PE2002000160A patent/PE20021008A1/es not_active Application Discontinuation
-
2004
- 2004-05-26 US US10/854,299 patent/US7476391B2/en not_active Expired - Lifetime
-
2009
- 2009-05-22 AR ARP090101850A patent/AR071888A2/es unknown
-
2010
- 2010-11-04 JP JP2010247585A patent/JP2011097938A/ja active Pending
-
2011
- 2011-04-18 CY CY20111100401T patent/CY1112014T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005502315A5 (enExample) | ||
| Lau et al. | A functional genomic analysis of type 3 Streptococcus pneumoniae virulence | |
| Young et al. | A bifunctional urease enhances survival of pathogenic Yersinia enterocolitica and Morganella morganii at low pH | |
| Graumann et al. | Some like it cold: response of microorganisms to cold shock | |
| Sarkari et al. | Variable expression of the Opc outer membrane protein in Neisseria meningitidis is caused by size variation of a promoter containing poly‐cytidine | |
| Mattos-Graner et al. | Cloning of the Streptococcus mutans gene encoding glucan binding protein B and analysis of genetic diversity and protein production in clinical isolates | |
| Wu et al. | Identification of dipeptide repeats and a cell wall sorting signal in the fimbriae‐associated adhesin, Fap1, of Streptococcus parasanguis | |
| Henze et al. | Staphylococcus aureus penicillin-binding protein 4 and intrinsic beta-lactam resistance | |
| US7824894B2 (en) | Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof | |
| Dietz et al. | Identification of target genes regulated by the two-component system HP166-HP165 of Helicobacter pylori | |
| WO2002075507B1 (en) | Anti-bacterial vaccine compositions | |
| Berish et al. | Molecular cloning and characterization of the structural gene for the major iron-regulated protein expressed by Neisseria gonorrhoeae. | |
| AU2003234043A1 (en) | Immunogenic sequences | |
| Harvey et al. | A variable region within the genome of Streptococcus pneumoniae contributes to strain-strain variation in virulence | |
| JP2004065257A (ja) | 特にグラム陽性菌に誘導型糖ペプチド耐性を付与するタンパク質 | |
| Beukes et al. | Self-protection against cell wall hydrolysis in Streptococcus milleri NMSCC 061 and analysis of the millericin B operon | |
| US5552273A (en) | Polypeptides containing sequences characteristic of pyrrolidone carboxylyl peptidases, polynucleotides containing a sequence coding for such polypeptides, and their use, in particular for diagnostic purposes | |
| Han et al. | Identification, molecular cloning, and sequence analysis of a deoxyribose aldolase in Streptococcus mutans GS-5 | |
| Middendorf et al. | Representational difference analysis identifies a strain-specific LPS biosynthesis locus in Bordetella spp. | |
| Bereswill et al. | Cloning and functional characterization of the genes encoding 3-dehydroquinate synthase (aroB) and tRNA-guanine transglycosylase (tgt) from Helicobacter pylori | |
| Han et al. | The Porphyromonas gingivalis prtP/kgp homologue exists as two open reading frames in strain 381 | |
| Brüggemann et al. | Clostridium botulinum | |
| Wang et al. | A UspA2H-negative variant of Moraxella catarrhalis strain O46E has a deletion in a homopolymeric nucleotide repeat common to uspA2H genes | |
| EP1878439A2 (en) | Actinobacillus pleuropneumoniae virulence genes | |
| Peruzzi et al. | Development of an integrative, lacZ transcriptional-fusion plasmid vector for Streptococcus mutans and its use to isolate expressed genes |